S&P 500   3,249.37 (-1.40%)
DOW   28,577.89 (-1.42%)
QQQ   218.42 (-1.92%)
AAPL   309.37 (-2.81%)
FB   215.10 (-1.30%)
MSFT   162.45 (-1.57%)
GOOGL   1,430.09 (-2.46%)
AMZN   1,830.27 (-1.69%)
CGC   21.66 (-4.37%)
NVDA   240.28 (-4.07%)
BABA   205.50 (-3.86%)
MU   55.50 (-3.91%)
TSLA   554.40 (-1.84%)
AMD   49.17 (-2.34%)
T   38.37 (-0.34%)
ACB   1.90 (-4.53%)
F   8.91 (-1.11%)
NFLX   342.01 (-3.16%)
DIS   136.03 (-2.89%)
S&P 500   3,249.37 (-1.40%)
DOW   28,577.89 (-1.42%)
QQQ   218.42 (-1.92%)
AAPL   309.37 (-2.81%)
FB   215.10 (-1.30%)
MSFT   162.45 (-1.57%)
GOOGL   1,430.09 (-2.46%)
AMZN   1,830.27 (-1.69%)
CGC   21.66 (-4.37%)
NVDA   240.28 (-4.07%)
BABA   205.50 (-3.86%)
MU   55.50 (-3.91%)
TSLA   554.40 (-1.84%)
AMD   49.17 (-2.34%)
T   38.37 (-0.34%)
ACB   1.90 (-4.53%)
F   8.91 (-1.11%)
NFLX   342.01 (-3.16%)
DIS   136.03 (-2.89%)
S&P 500   3,249.37 (-1.40%)
DOW   28,577.89 (-1.42%)
QQQ   218.42 (-1.92%)
AAPL   309.37 (-2.81%)
FB   215.10 (-1.30%)
MSFT   162.45 (-1.57%)
GOOGL   1,430.09 (-2.46%)
AMZN   1,830.27 (-1.69%)
CGC   21.66 (-4.37%)
NVDA   240.28 (-4.07%)
BABA   205.50 (-3.86%)
MU   55.50 (-3.91%)
TSLA   554.40 (-1.84%)
AMD   49.17 (-2.34%)
T   38.37 (-0.34%)
ACB   1.90 (-4.53%)
F   8.91 (-1.11%)
NFLX   342.01 (-3.16%)
DIS   136.03 (-2.89%)
S&P 500   3,249.37 (-1.40%)
DOW   28,577.89 (-1.42%)
QQQ   218.42 (-1.92%)
AAPL   309.37 (-2.81%)
FB   215.10 (-1.30%)
MSFT   162.45 (-1.57%)
GOOGL   1,430.09 (-2.46%)
AMZN   1,830.27 (-1.69%)
CGC   21.66 (-4.37%)
NVDA   240.28 (-4.07%)
BABA   205.50 (-3.86%)
MU   55.50 (-3.91%)
TSLA   554.40 (-1.84%)
AMD   49.17 (-2.34%)
T   38.37 (-0.34%)
ACB   1.90 (-4.53%)
F   8.91 (-1.11%)
NFLX   342.01 (-3.16%)
DIS   136.03 (-2.89%)
Log in

NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

$9.46
-0.04 (-0.42 %)
(As of 01/27/2020 02:55 PM ET)
Today's Range
$9.42
Now: $9.46
$9.56
50-Day Range
$7.74
MA: $8.84
$10.41
52-Week Range
$5.96
Now: $9.46
$11.35
Volume1,380 shs
Average Volume181,980 shs
Market Capitalization$369.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.97 million
Book Value$2.69 per share

Profitability

Net Income$-49,690,000.00
Net Margins-1,461.28%

Miscellaneous

Employees146
Market Cap$369.79 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.


Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

8 equities research analysts have issued twelve-month price targets for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.44 in the next year. This suggests a possible upside of 52.6% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Has Kindred Biosciences been receiving favorable news coverage?

Media coverage about KIN stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Kindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 671,100 shares, a decrease of 5.5% from the November 28th total of 709,900 shares. Based on an average trading volume of 98,200 shares, the days-to-cover ratio is currently 6.8 days. Currently, 1.8% of the company's shares are sold short. View Kindred Biosciences' Current Options Chain.

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $9.46.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $369.79 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is http://kindredbio.com/.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  649
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel